These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35880450)

  • 1. Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas.
    Goldsmith SR; Liu L; Shiah K
    Curr Opin Oncol; 2022 Sep; 34(5):524-530. PubMed ID: 35880450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.
    Nooka AK; Costa LJ; Gasparetto CJ; Richardson PG; Siegel DS; Chari A; Lentzsch S; Jagannath S; Mikhael J
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e526-e531. PubMed ID: 35361554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Latest Research Progress of Selinexor in the Treatment of Non-Hodgkin Lymphoma --Review].
    Tang XY; Wang Y; Xu RR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):292-296. PubMed ID: 36765514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
    Peterson TJ; Orozco J; Buege M
    Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
    [No Abstract]   [Full Text] [Related]  

  • 5. Selinexor for the treatment of multiple myeloma.
    Podar K; Shah J; Chari A; Richardson PG; Jagannath S
    Expert Opin Pharmacother; 2020 Mar; 21(4):399-408. PubMed ID: 31957504
    [No Abstract]   [Full Text] [Related]  

  • 6. Selinexor in multiple myeloma.
    Martino EA; Vigna E; Bruzzese A; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Torricelli F; Neri A; Morabito F; Gentile M
    Expert Opin Pharmacother; 2024 Mar; 25(4):421-434. PubMed ID: 38503547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
    Schuster M; Zijlstra J; Casasnovas RO; Vermaat JSP; Kalakonda N; Goy A; Choquet S; Neste EVD; Hill B; Thieblemont C; Cavallo F; De la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Follows G; Egyed M; Offner F; Vassilakopoulos T; Samal P; Ku M; Ma X; Corona K; Chamoun K; Shah J; Shacham S; Kauffman MG; Canales M; Maerevoet M
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):483-494. PubMed ID: 35078739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
    Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
    J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selinexor: First Global Approval.
    Syed YY
    Drugs; 2019 Sep; 79(13):1485-1494. PubMed ID: 31429063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selinexor for the treatment of patients with previously treated multiple myeloma.
    Mo CC; Jagannath S; Chari A; Nooka AK; Lonial S; Siegel D; Biran N; Gasparetto C; Bahlis NJ; Richardson P
    Expert Rev Hematol; 2021 Aug; 14(8):697-706. PubMed ID: 33985401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
    Turner JG; Cui Y; Bauer AA; Dawson JL; Gomez JA; Kim J; Cubitt CL; Nishihori T; Dalton WS; Sullivan DM
    Cancer Res; 2020 Dec; 80(23):5344-5354. PubMed ID: 33023948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Kasamon YL; Price LSL; Okusanya OO; Richardson NC; Li RJ; Ma L; Wu YT; Theoret M; Pazdur R; Gormley NJ
    Oncologist; 2021 Oct; 26(10):879-886. PubMed ID: 34132444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma.
    Sylvain C
    Expert Rev Hematol; 2022 Mar; 15(3):195-201. PubMed ID: 35318887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis.
    Shafei L; Bashir S; Chan EW; Abushanab D; Hamad A; Al-Badriyeh D
    Curr Probl Cancer; 2024 Jun; 50():101076. PubMed ID: 38537395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 'comeback' of Selinexor: From toxic to tolerable.
    Hashmi H; Green K
    Curr Probl Cancer; 2022 Feb; 46(1):100789. PubMed ID: 34479762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
    Chen C; Siegel D; Gutierrez M; Jacoby M; Hofmeister CC; Gabrail N; Baz R; Mau-Sorensen M; Berdeja JG; Savona M; Savoie L; Trudel S; Areethamsirikul N; Unger TJ; Rashal T; Hanke T; Kauffman M; Shacham S; Reece D
    Blood; 2018 Feb; 131(8):855-863. PubMed ID: 29203585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
    Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
    J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.